Garmin (Venu / Fenix / Forerunner) vs Whoop (5.0 / MG) in 2026

Garmin (Venu / Fenix / Forerunner)

Garmin (the Venu 3 as the biometric-primary anchor at about $449; the Fenix 8 and Forerunner 965 are more athletics-primary and pricier) is the lightest-cleared-portfolio entry in the biometric cohort. Its sensors (Elevate optical heart rate, Pulse Ox/SpO2, ECG on select models, skin temperature) drive Body Battery, Training Load and Training Readiness, advanced sleep and a sleep coach, all-day stress and HRV Status, and a Morning Report.

The verified-vs-claimed distinction matters here: only the ECG is FDA-cleared (a 510(k) in 2023, on select models); Body Battery, recovery, and the broader readiness metrics are wellness-grade, and Pulse Ox is not FDA-cleared. Garmin is purchase-only (founded 1989); the optional Garmin Connect+ AI subscription ($6.99/month, March 2025) does not gate any existing features. DEPLOY cap-flags any reading of Garmin's wellness metrics as cleared diagnostics; only the ECG carries a clearance.

Whoop (5.0 / MG)

Whoop (the 5.0 and the 'Medical Grade' MG, both launched May 8, 2025, from Whoop, founded 2012 in Boston by Will Ahmed) is a screen-free biometric wrist band and the subscription-only archetype of the biometric cohort: there is no standalone hardware sale. Access is a membership, Whoop One at $199/year, Peak at $239/year, and Life at $359/year (which includes the MG hardware), with the band provided inside the subscription.

Its PPG, skin-temperature, SpO2, and respiratory sensors feed Strain, Recovery, and Sleep Coach analytics and an LLM 'Whoop Coach'; the MG adds ECG, Blood Pressure Insights, and a Healthspan / 'Whoop Age' feature. DEPLOY records commercial maturity and a reported $10.1 billion valuation (March 2026).

Whoop is the strongest verified-vs-claimed cautionary exemplar in the cohort: its ECG is FDA-cleared (2025), but it marketed Blood Pressure Insights without clearance, drew an FDA Warning Letter on July 14, 2025, refused to remove the feature, and as of May 2026 the matter is unresolved with a class action filed, the market-first contrast to Oura's study-first posture.